Loading clinical trials...

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITINGNA

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

Behavioral Change Following Culturally Informed Biomarker Disclosure in Alzheimer's Disease

NCT05584241•University of Michigan

Summary

The proposed project will assess long-term changes to health/lifestyle, advanced planning, and research engagement that Black and White patients with Amnestic Mild Cognitive Impairment (aMCI) make following disclosure of positron emission tomography-based amyloid and tau burden and associated risk of conversion to Dementia-Alzheimer's Type. Healthcare access will be explored as potential barrier to or facilitator of behavior change.

Eligibility

Age

50 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosed with Amnestic Mild Cognitive Impairment within the past 12 months,
•Available PET Aβ and tau imaging

Exclusion Criteria

•Significant neurologic diagnosis (e.g., Alzheimer's dementia or other neurodegenerative dementia, Parkinson's disease, seizure disorder, tumor, multiple sclerosis)
•Neurologic injury (e.g., significant stroke or moderate-severe head injury, defined by loss of consciousness \> 5 minutes, presence of significant post-traumatic amnesia, or the need for extended hospitalization or intervention)
•Motor abnormalities indicative of a non-AD etiology
•Severe mental illness (e.g., bipolar disorder, psychosis), moderate-severe mood or anxiety disorder, active substance use disorder (o reduce the likelihood of severe psychological distress, participants must screen negative for moderate-severe depressive or anxiety symptoms at study enrollment.)
•Inability to provide independent informed consent.

Locations (1)

The University of Michigan

Ann Arbor, Michigan, United States

Key Dates

Start Date

February 20, 2023

Primary Completion Date

May 1, 2026

Completion Date

May 1, 2026

Last Updated

January 8, 2026

Enrollment

100

ESTIMATED participants

Conditions

Mild Cognitive ImpairmentAlzheimer DiseaseAmnestic Mild Cognitive Disorder

Interventions

Diagnostic Disclosure Protocol

BEHAVIORAL

Biomarker Disclosure Protocol

BEHAVIORAL

Sense4Safety Intervention

NCT07220668

Mild Cognitive Impairment

View study

RECRUITINGEARLY_PHASE1

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

NCT04123314

Depressive SymptomsDepression+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 8, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Behavioral Change Following Alzheimer's Disease (AD) Biomarker Disclosure

Inclusion Criteria

Exclusion Criteria

Sense4Safety Intervention

Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease

Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease

Validating the On-line Creyos Cognitive Assessment Platform in Older Adults With Major Depressive Disorder or Mild Cognitive Impairment

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases